Cholankeril George, Perumpail Ryan B, Hu Menghan, Skowron Gail, Younossi Zobair M, Ahmed Aijaz
Department of Internal Medicine, Roger Williams Medical Center, Boston University School of Medicine, 825 Chalkstone Avenue, Providence, RI, 02908, USA.
Division of Gastroenterology and Hepatology, Stanford University School of Medicine, 300 Pasteur Drive, Grant S101, Stanford, CA, 94305, USA.
Dig Dis Sci. 2016 Sep;61(9):2505-15. doi: 10.1007/s10620-016-4160-z. Epub 2016 Apr 15.
Chronic hepatitis B virus (HBV) and chronic hepatitis C virus (HCV) infections remain one of the leading causes of chronic liver disease and hepatocellular carcinoma. Healthcare initiatives for chronic viral hepatitis to facilitate early diagnosis and linkage to care in an effort to reduce inpatient resource utilization associated with late diagnosis and end-stage liver disease have been partially successful.
Our objective was to determine the impact of liver-related complications from chronic HBV and HCV infections on inpatient cost of care, length of stay, and mortality.
Using the Healthcare Cost and Utilization Project, National Inpatient Sample (HCUP-NIS), we studied the impact of chronic HBV and HCV infections on inpatient healthcare system following hospitalizations from 2003 to 2012.
Of the 79,185,729 million hospitalizations among adult patients in the USA from 2003 to 2012, 143,896 (0.18 %) hospitalizations were HBV related and 1,073,269 (1.36 %) hospitalizations HCV related. HBV hospitalizations had a higher inpatient mortality (OR 1.34; 95 % CI 1.30, 1.38), median cost of care per hospitalization (+$2100.33; 95 % CI 1982.53, 2217.53), and increased length of hospitalization stay (+0.64 days; 95 % CI 0.60, 0.68; p < 0.01) compared to HCV.
Despite higher per case resource utilization following hospitalization, HBV-infected patients demonstrate a lower inpatient survival in comparison with chronic HCV infection. These disparate observations underscore the need for early diagnosis of chronic HBV infection in at-risk population and prompt linkage to care.
慢性乙型肝炎病毒(HBV)和慢性丙型肝炎病毒(HCV)感染仍然是慢性肝病和肝细胞癌的主要病因之一。旨在促进慢性病毒性肝炎早期诊断及与治疗衔接以减少与晚期诊断和终末期肝病相关的住院资源利用的医疗保健举措已取得部分成功。
我们的目标是确定慢性HBV和HCV感染所致肝脏相关并发症对住院护理费用、住院时间和死亡率的影响。
利用医疗保健成本与利用项目的国家住院患者样本(HCUP-NIS),我们研究了2003年至2012年住院后慢性HBV和HCV感染对住院医疗系统的影响。
2003年至2012年美国成年患者的79185729次住院中,143896次(0.18%)住院与HBV相关,1073269次(1.36%)住院与HCV相关。与HCV相比,HBV住院患者的住院死亡率更高(比值比1.34;95%置信区间1.30,1.38),每次住院护理费用中位数更高(增加2100.33美元;95%置信区间1982.53,2217.53),住院时间更长(增加0.64天;95%置信区间0.60,0.68;p<0.01)。
尽管住院后每例患者的资源利用率较高,但与慢性HCV感染相比,HBV感染患者的住院生存率较低。这些不同的观察结果强调了对高危人群慢性HBV感染进行早期诊断并迅速与治疗衔接的必要性。